WILLOW BIOSCIENCES INC - CANSF STOCK NEWS

Willow Biosciences Inc. (TSX: WLLW, OTCQB: CANSF), a biotechnology leader, will host a webcast investor presentation on November 10, 2022, at 2:00 PM EST. The event will feature Willow's President and CEO, Dr. Peter Seufer-Wasserthal, and VP of Corporate Development, Troy Talkkari, discussing the company’s strategic areas. Investors can engage through a Q&A session. Pre-registration is required to access the live presentation. An archived version will be available on the company's website after the event.

Willow Biosciences Inc. (OTCQB: CANSF) announced its financial results for Q3 2022, reflecting strong liquidity with $18.7 million in working capital and $18.4 million in cash. The company appointed Dr. Peter Seufer-Wasserthal as President and CEO effective November 3, 2022, who had been interim CEO since July 2022. Willow is advancing its FutureGrown™ technology platform and has completed proof of concept for Astaxanthin. The company remains optimistic despite challenges in the cannabinoid market and is focusing on partnerships in the food and personal care sectors.

Willow Biosciences has successfully completed proof of concept and initiated yeast strain optimization for commercial production of astaxanthin, a potent antioxidant used in various industries. This development aims to meet the growing demand for natural, sustainably produced astaxanthin, currently valued at approximately $US 750 million with an expected growth rate of 8% annually. The company leverages its FutureGrown™ technology platform to produce cost-effective, high-purity astaxanthin. Willow plans to update stakeholders on key milestones and potential partnerships.

Willow Biosciences Inc. (OTCQB: CANSF) announced updates on its cannabigerol (CBG) product, focusing on operational advancements and regulatory progress. The Company is expanding its manufacturing network and expects to produce the first commercial CBG batches in H1 2023. Willow has successfully completed Stage 1 of the Generally Recognized as Safe (GRAS) assessment for its FutureGrown™ CBG and aims to initiate Stage 2 by Q3 2022. The Company has filed 12 patent applications related to cannabinoid production, positioning itself for sustained growth in the biosynthetic market.

Willow Biosciences Inc. (OTCQB: CANSF) reported its second quarter 2022 results, showcasing operational advancements, strong leadership, and robust liquidity with $22.1 million in working capital. The company is progressing with a pharmaceutical partnership and expanding its manufacturing capabilities to support FutureGrown™ CBG production. Highlights include successful toxicological assessments, new manufacturing partnerships, and a consolidation of R&D operations in California. Despite challenges in the cannabinoid market, Willow remains focused on long-term growth and product development.

Willow Biosciences has appointed Dr. Peter Seufer-Wasserthal as Interim President and CEO as of July 17, 2022, following the retirement of Trevor Peters. Dr. Seufer-Wasserthal, previously the Chairman of the Board, aims to lead the company in expanding its product portfolio and forging strategic partnerships. Barbara Munroe has been appointed as Lead Independent Director. Willow's commitment to developing sustainable, high-purity ingredients positions it for growth in the biotech sector, particularly in nutrition, food and beverage, and consumer care markets.

Willow Biosciences Inc. (CANSF) announced significant developments on May 11, 2022. The company entered a Manufacturing Services Agreement with a second Contract Development and Manufacturing Organization (CDMO), enhancing its fermentation production capacity for FutureGrown™ products, including cannabigerol (CBG). In addition, Willow has completed the initial Stage 1 toxicological assessment of FutureGrown™ CBG, indicating it is non-mutagenic, a crucial step towards obtaining Generally Recognized as Safe (GRAS) status in the United States.

Willow Biosciences Inc. (OTCQB: CANSF) announced a live webcast investor presentation on February 3rd, 2022, at 2:00 PM EST. President and CEO Trevor Peters will discuss key business areas and engage with investors through a Q&A session. Interested participants must pre-register for the event through the provided link. An archived version of the presentation will be accessible on the company's website afterward. Willow specializes in sustainable cannabinoid production using its FutureGrown™ platform, aiming to benefit various markets.

Willow Biosciences has announced positive results from its first peer-reviewed study on cannabigerol (CBG), detailing its benefits for skincare. Conducted with Signum Biosciences, the study showcased that Willow's FutureGrown CBG significantly reduces skin inflammation and improves barrier function in a clinical trial involving 20 participants. These findings highlight CBG's promise as a skincare ingredient, outperforming cannabidiol (CBD) in several aspects. The study's publication in the journal Molecules adds credibility to Willow's ongoing research in the cannabinoid industry.